Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Sensorion

< Previous 1 2 3 Next >
Sensorion Appoints Dr. Federico Mingozzi as Non-Executive Director to the Board of Directors
From Sensorion
Via Business Wire
Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate SENS-501 (OTOF-GT) into a Phase 1/2 Clinical Trial in some European Countries
From Sensorion
Via Business Wire
Sensorion Announces Partnership With the Institut Pasteur to Accelerate Gene Therapy Programs Targeting Hearing Disorders Has Been Extended for Five Years
From Sensorion
Via Business Wire
Sensorion Publishes Results of Combined General Meeting Resolutions
From Sensorion
Via Business Wire
Sensorion Provides an Update on NOTOXIS, its Proof of Concept Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity (CIO)
From Sensorion
Via Business Wire
Sensorion Appoints CMC Expert Bernd Schmidt as New Chief Technical Officer
From Sensorion
Via Business Wire
Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of December 20, 2023
From Sensorion
Via Business Wire
Sensorion Announces Its Attendance at the 42nd Annual J.P. Morgan Healthcare Meeting in San Francisco
From Sensorion
Via Business Wire
Sensorion to Participate in the Jefferies London Healthcare Conference and McDermott Will & Emery’s Life Sciences Symposium
From Sensorion
Via Business Wire
Sensorion Will Present At The European Society Of Gene & Cell Therapy (ESGCT) Conference
From Sensorion
Via Business Wire
Sensorion Announces the Availability of Its Financial Report for the 1st Half of 2023
From Sensorion
Via Business Wire
Sensorion Announces Webconference on September 25, 2023, and its Participation in Upcoming Investor Conferences in October 2023
From Sensorion
Via Business Wire
Sensorion Reports 2023 First Half Results
From Sensorion
Via Business Wire
Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe
From Sensorion
Via Business Wire
Sensorion Submits Clinical Trial Application for Lead Gene Therapy Candidate OTOF-GT in the UK
From Sensorion
Via Business Wire
Sensorion Reports Positive Efficacy Data from SENS-401 Phase 2a Clinical Study
From Sensorion
Via Business Wire
Sensorion Reports Promising Preliminary Data from SENS-401 Phase 2a Clinical Study
From Sensorion
Via Business Wire
Sensorion to Host Key Opinion Leader Webinar on July 5, 2023; Confirms Upcoming Key Milestones
From Sensorion
Via Business Wire
Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions
From Sensorion
Via Business Wire
Sensorion Will Present Two Posters At The American Society Of Cell And Gene Therapy (ASGCT) 26th Annual Meeting
From Sensorion
Via Business Wire
Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 24, 2023
From Sensorion
Via Business Wire
Sensorion to Host a Symposium during ISIET’s International Symposium on Inner Ear Therapeutics on April 30, 2023
From Sensorion
Via Business Wire
Sensorion to participate in Chardan’s Annual Genetic Medicines & Cell Therapy Manufacturing Summit and Kempen’s Life Sciences Conference
From Sensorion
Via Business Wire
Sensorion Announces Candidate Selection for GJB2 Gene Therapy Program
From Sensorion
Via Business Wire
Sensorion Appoints Khalil Barrage as Interim Chairman of the Board
From Sensorion
Via Business Wire
Sensorion Announces the Publication of Its 2022 Annual Financial Report
From Sensorion
Via Business Wire
Sensorion Reports Full-Year 2022 Financial Results and Business Update
From Sensorion
Via Business Wire
Sensorion Announces Agenda For R&D Day Showcasing Gene Therapy For Inner Ear Disease
From Sensorion
Via Business Wire
Sensorion Discloses No Exposure To Silicon Valley Bank Closure
From Sensorion
Via Business Wire
Sensorion to Participate in the 6th Annual Bioprocessing Summit Europe
From Sensorion
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.